BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Transforming Proteins into Pioneering Drugs - ProJect Pharmaceutics Started Operations


12/13/2010 10:40:27 AM

Munich, Germany, December 13, 2010 / b3c newswire / – ProJect Pharmaceutics started business operations and opened its laboratory facilities in the Biotech-cluster in Martinsried, near Munich. ProJect Pharmaceutics (PJP) transforms proteins, peptides and delicate small molecules into pioneering drugs.

Adding value to client´s bio-therapeutic products is PJP´s mission, focused in an innovative concept of biopharmaceutical development called Advaceutics. Based on the Advaceutics concept, ProJect Pharmaceutics designs optimized pharmaceutical formulations and delivery systems that are stable, convenient and safe. Tailored to these optimized systems the company develops cost-effective manufacturing processes and transfers those from its own pilot labs to large-scale manufacturing. ProJect Pharmaceutics makes sure that investigational products as well as new presentations of registered drugs are developed effectively and will run smoothly in clinical and commercial scale GMP manufacturing.

ProJect Pharmaceutics was founded and is managed by Andreas Schütz and Klaus Hellerbrand, two leading experts in protein formulation and pharmaceutical process development with many years of experience in bio-pharmaceutics. Their combined expertise and complementary set of qualifications enables ProJect Pharmaceutics to deliver the high-tech pharmaceutical services the team is known for and that are in increased demand for the global biopharmaceutical industry. “In times of an increasingly globalizing and changing pharmaceutical value chain, capital efficiency in developing new drugs, paired with deep expertise and highly reliable quality of service are ever important for competitive pharmaceutical companies facing a challenging market environment”, says Dr. Andreas Schütz, Managing Director and Founder of ProJect Pharmaceutics. “We started our operations with an experienced team of biopharmaceutical professionals and already are working on several exciting projects“, comments Klaus Hellerbrand, Managing Director and Founder.

ProJect Pharmaceutic management profile:

Andreas Schütz, Managing Director & Founder

Andreas Schütz is an inventor of numerous patents and patent applications. His key expertise is focused on Formulation Science, Drug Delivery Systems, Lyophilisation Technology, Aseptic Processing, Project and Key Account Management. He founded ProJect Pharmaceutics in 2010 together with Klaus Hellerbrand. Prior to starting his own company, he was VP Pharmaceutical Development and Head of BioPharma Services at Scil Technologies, Munich, Germany where he had joined in 2001. Dr. Schütz studied Pharmacy and received his PhD in Pharmaceutical Technology from the University of Erlangen in 1991. He began his career in pharmaceutical development with Schwarz Pharma AG, Monheim, Germany and held the position of Head of Specialized Pharmaceutical Systems prior to joining Vetter Pharma, Ravensburg, Germany in 1998 as Head of Pharmaceutical Development and Senior Project Manager.

Klaus Hellerbrand, Managing Director & Founder

Klaus Hellerbrand is an inventor of numerous patents and patent applications. He is an expert in Protein Science, Protein Analytics, Down-stream Processing, Process Technology, Coating Technology and Lyophilisation Technology. He founded ProJect Pharmaceutics in 2010 together with Dr. Andreas Schütz. Prior to his entrepreneurial activity he worked as Head of Pharmaceutical Technology at Scil Technology, Munich, Germany where he joined in 1999 as protein formulation scientist. Klaus Hellerbrand earned his degree of applied Science in Biotechnology from the University of Weihenstephan. In 1995 he joined Boehringer Mannheim/ Roche Diagnostics as a development engineer focused on down-stream processes for protein drugs and development of protein formulations.

For more information please visit: www.project-pharmaceutics.com or contact:

ProJect Pharmaceutics GmbH Fraunhoferstraße 22 D-82152 Martinsried +49 (0) 89 452289700

Dr. Andreas Schütz: andreas.schuetz@project-pharmaceutics.com Klaus Hellerbrand: klaus.hellerbrand@project-pharmaceutics.com

Media Relations: DenkLeistung Kommunikation Monika Schlesinger +49 (0)8141 539702 monika.schlesinger@t-online.de



Read at BioSpace.com

 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES